JAC Advance Access published online on December 6, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm476
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading article |
Tissue concentrations: do we ever learn?
1 Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands 2 Center for Anti-Infective Agents, Vienna, Austria 3 Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 4 Cellular and Molecular Pharmacology Unit, Université catholique de Louvain, Brussels, Belgium 5 Department of Pharmaceutics, University of Florida, Gainesville, FL, USA 6 Department of Medical Sciences, Infectious Diseases, Uppsala University, Uppsala, Sweden
* Corresponding author. Tel: +31-24-3657514; Fax: +31-24-3657516; E-mail: mouton{at}cwz.nl
Over the last decades, numerous papers have appeared—and still are appearing—that describe concentrations in tissues in an effort to predict the efficacy of an antimicrobial agent based on these concentrations and MICs for microorganisms. A common method is to use measurements of concentrations in tissue homogenates, comparing these with values derived from the corresponding blood samples and on that basis draw conclusions with respect to the potential clinical use of the drug. This approach is not justifiable for a number of reasons that includes both pharmacokinetic as well as pharmacodynamic causes. This way of presenting data with the derived conclusions is often misleading and may ultimately be harmful in patient care.
Key Words: homogenizing , tissue distribution , pharmacodynamics , pharmacokinetics
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Lemaire, F. Van Bambeke, P. C. Appelbaum, and P. M. Tulkens Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines J. Antimicrob. Chemother., November 1, 2009; 64(5): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. O. Gubbins, J. R. Amsden, S. A. McConnell, and E. J. Anaissie Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3664 - 3674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lemaire, F. Van Bambeke, and P. M. Tulkens Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in Human THP-1 Macrophages Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3734 - 3743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Roberts, C. M. J. Kirkpatrick, M. S. Roberts, T. A. Robertson, A. J. Dalley, and J. Lipman Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution J. Antimicrob. Chemother., July 1, 2009; 64(1): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barbour, S. Schmidt, S. N. Sabarinath, M. Grant, C. Seubert, D. Skee, B. Murthy, and H. Derendorf Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2773 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Landersdorfer, M. Kinzig, J. B. Bulitta, F. F. Hennig, U. Holzgrabe, F. Sorgel, and J. Gusinde Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by Population Pharmacokinetics and Monte Carlo Simulation Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2569 - 2578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Landersdorfer, M. Kinzig, F. F. Hennig, J. B. Bulitta, U. Holzgrabe, G. L. Drusano, F. Sorgel, and J. Gusinde Penetration of Moxifloxacin into Bone Evaluated by Monte Carlo Simulation Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2074 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Zeller, F. Durand, M.-D. Kitzis, L. Lhotellier, J.-M. Ziza, P. Mamoudy, and N. Desplaces Continuous Cefazolin Infusion To Treat Bone and Joint Infections: Clinical Efficacy, Feasibility, Safety, and Serum and Bone Concentrations Antimicrob. Agents Chemother., March 1, 2009; 53(3): 883 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marchand, D. Frasca, C. Dahyot-Fizelier, C. Breheret, O. Mimoz, and W. Couet Lung Microdialysis Study of Levofloxacin in Rats following Intravenous Infusion at Steady State Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3074 - 3077. [Abstract] [Full Text] [PDF]
|
|